ABSTRACT

Introduction The objective of this randomised controlled trial (RCT) is to examine the effects of smartphone-based cognitive–behavioural therapy (CBT) in preventing the onset of major depressive episodes (MDE) among pregnant women.

Methods and analysis The target study population will be pregnant women of 16–20 weeks gestation who are currently users of ‘Luna Luna Baby’, the most widely used app for pregnant women in Japan. Those who meet the eligibility criteria will be randomly allocated to the 6-module internet CBT programme that was newly developed for pregnant women (n=2500), or to a treatment-as-usual control group (n=2500). Participants in the intervention groups will be required to complete the programme by 32 weeks gestation. The primary outcomes are the number of new onsets of MDE, measured by using WHO Composite International Diagnostic Interview 3.0 at 32 weeks gestation and 3 months post partum. Survival analysis will be conducted to test for the effectiveness of the intervention on the time to the onset of MDE.

Ethics and dissemination The study plan has been approved by the Research Ethics Review Board of the Graduate School of Medicine/Faculty of Medicine, the University of Tokyo (2019150NI). If the intervention programmes are found to produce a significant positive effect in this RCT, these programmes can be made available for all users of the app in the future.

Trial registration number UMIN000038190; Pre-results.

INTRODUCTION

Prevention of perinatal depression is a critical public health issue. The prevalence of antenatal depression was reported to be 7.4% in the first trimester, 12.8% in the second trimester and 12.0% in the third trimester; and the prevalence of postpartum depression was estimated to be 17.7%, though there is significant heterogeneity across nations. Antenatal depression is associated with failing to seek prenatal care, an inadequate diet and/or use of tobacco, alcohol, or other harmful substances, self-harm or attempted suicide, and postpartum depression, while postpartum depression is associated with negative outcomes such as physical and psychological abuse to their children, and infanticide. Furthermore, perinatal depression can also affect development from fetus to adolescent and paternal depression. Therefore, preventing perinatal depression in the antenatal period is crucially important.

Given the large number of pregnant women who have risk factors such as maternal anxiety, life stress, lack of social support, unintended pregnancy, domestic violence, lower income and education, and poor relationships, making it difficult to identify and screen all high-risk pregnant women,
universal prevention should be more valued. According to a systematic review and meta-analysis, psychological interventions have been recommended as the most effective approach to prevent antenatal and postpartum depression. Cognitive–behavioural therapy (CBT) has been broadly researched and reported to be highly effective among psychological interventions. Previous meta-analyses showed that the effect size of psychological intervention as universal prevention, which refers to approaches designed for the whole population regardless of individual risk factors, for postpartum depression was reported to be 0.19 and 0.37. The timing of interventions of randomised controlled trials (RCTs) included in these meta-analyses was both during pregnancy and postpartum.

With respect to universal prevention, fully automated internet-based CBT (iCBT) is preferable to face-to-face or guided iCBT in terms of accessibility, anonymity and cost effectiveness. Although a systematic review showed a positive effect of iCBT for the improvement of perinatal depressive symptoms, to our knowledge, there have been only two RCTs for universal prevention using automated iCBT during pregnancy. These two studies did not assess the major depressive episode (MDE); instead, they used depressive symptoms as outcomes. In addition, a dropout from iCBT in these studies was relatively high (66% and 44%, respectively). A large number of sessions and/or the length per session may be impractical for a substantial number of pregnant women to complete, which may cause a high dropout rate. Thus, it would be necessary to develop a programme that is more acceptable and feasible for pregnant women. In this regard, six sessions of 5–10 min iCBT programmes were shown to be effective for preventing depressive symptoms for workers.

Moreover, to our knowledge, no previous RCTs have examined the effect of iCBT on maternity blues. Maternity blues were characterised by psychological distress with a peak at 3–5 days after childbirth, though diagnostic criteria have not been well established. Maternity blues are highly prevalent and have been shown to be a risk factor for postpartum depression; thus, it would be relevant to develop the intervention to prevent not only perinatal depression but also maternity blues.

The primary objective of this RCT is to examine the effectiveness of the newly developed six sessions of 5–10 min, smartphone-based, automated CBT programmes in preventing the onset of MDE at the third trimester and 3 months post partum among pregnant women currently in the second trimester. The secondary objectives are to examine the effectiveness of iCBT for preventing maternity blues. The programme would be practical and could be used by many pregnant women. In addition, intervention during early pregnancy will enable the prevention of not only postpartum depression but also antenatal depression.

METHODS AND ANALYSIS

Trial design

The study will be a two-arm, parallel-group, treatment-as-usual (TAU) controlled, randomised trial. The allocation ratio of the intervention groups to the control group is 1:1. Random assignments are stratified by Kessler’s Psychological Distress Scale (K6) scores (groups of four points or less and groups of five points or more) in the baseline survey. K6 is a self-report questionnaire, which assesses psychological distress during the past 30 days. Users of the app (‘Luna Luna Baby’ run by MTI) will be recruited. The app provides the users for the growth of the fetus and the mental and physical condition of the pregnant women according to the number of gestation weeks. Users register the date of the last menstruation in the app; thus, we can find out the number of weeks of pregnancy.

Follow-up assessments will be conducted at 32 weeks gestation and 3 months post partum. This protocol is written in accordance with the Standard Protocol Items: Recommendations for Interventional Trials guideline checklist. The trial start date was 27 November 2019, and the last follow-up date will be 31 March 2021.

Participants

Pregnant women who have user identifications for the latest version of the app and meet the following criteria will be invited to participate in this RCT. Both primipara and multiparous women will be included.

Eligibility criteria

1. Being over 20 years old.
2. Being 16–20 weeks gestation.
3. Not diagnosed with an MDE in the past month by the web-based self-administered version of WHO Composite International Diagnostic Interview 3.0 (WHO-CIDI 3.0).
4. Not diagnosed with lifetime bipolar disorder (WHO-CIDI 3.0).

Recruitment

Figure 1 shows the study flow of this trial. MTI sends an invitation message to potentially eligible pregnant women, which will include an explanation of the study and information on the eligibility criteria. After reading the explanation of the study, potential participants will be invited to give their consent on the app to participate in the study and to complete and return the baseline survey. MTI will also send messages to study participants to join in follow-up assessments.

Five thousand pregnant women will be randomised to either the intervention group (n=2500), or the control group (n=2500). Participants in the intervention groups will be required to complete the intervention programme up to 32 weeks gestation. Participants will be invited to share this information through any social network. The participants will be reminded by a popup message to complete the programme if they have not already done...
so. Intervention programmes will be closed at 32 weeks gestation.

Participants in the control group will not receive any intervention programmes during the intervention and follow-up period. General information about mental health during pregnancy will be provided to participants in both the intervention group and the control group as a TAU.

Interventions
A smartphone-based six-module CBT programme designed for pregnant women was newly developed. Specifically, the first author (DN) developed the iCBT programme with the collaboration of coauthors (KI, EO, NS and YS). The programme was tailored for pregnant women by extracting essential topics that pregnant women are concerned about. The details were shown in the Patient and public involvement section. This programme will be provided via the Luna Luna Baby app, so users of the app do not have to download another app. Some components of the modules were derived from a previous iCBT programme that successfully prevented the onset of MDE among office workers.20 Other components such as behavioural activation based on values, self-compassion and mindfulness have been incorporated, which could be regarded as the third wave CBT. The six modules are presented in a fixed order, with one module accessible per week, from module 1 to module 6 (table 1).

It will take about 5 min to complete each module. The programme includes psychoeducation (module 1), case formulation based on a cognitive–behavioural (CB) model (module 2), behavioural activation (module 3), self-compassion (module 4), mindfulness (module 5) and problem solving (module 6). Details of each of the components are as follows.

| Module no | Techniques for stress management |
|-----------|----------------------------------|
| Module 1  | Psychoeducation                  |
| Module 2  | Case formulation based on cognitive–behavioural model |
| Module 3  | Behavioural activation           |
| Module 4  | Self-compassion                  |
| Module 5  | Mindfulness                      |
| Module 6  | Problem solving                  |

Psychoeducation (module 1)
In this module, participants learn about the roles of what are generally called ‘negative’ emotions such as anxiety, depressive mood and anger. Each emotion is necessary for us; for example, anxiety is a sign that warns us of some risk in the future and promotes us to prepare for the future. This module was designed to help participants face and deal with their own emotions in subsequent modules. As an example of anxious situations, a scene that a partner of a pregnant woman is busy working and is not at home is used. As an example of sad situations, a scene when a pregnant woman suffers from morning sickness but the boss does not understand is used.

Case formulation based on CB model (module 2)
In this module, participants learn about a CB model, especially the five-part model (situation, thoughts, emotions, behaviour and physical sensations) and a case formulation based on this model.24 Case formulation is a method used to understand the problems of patients or clients. Case formulation is helpful for participants to choose an appropriate approach to change the vicious circles of these five areas. A scene when a pregnant woman suffers from morning sickness but the boss does not understand is used as a case.

Behavioural activation (module 3)
Behavioural activation is a process to increase pleasurable and rewarding activities using behavioural strategies such as activity scheduling. This module provides a behavioural activation technique for enhancing participants’ liveliness. In this module, participants learn about the theory of behavioural activation and how to plan an activity schedule to increase pleasant activities. Participants are also encouraged to identify their values based on brief behavioural activation therapy for depression,25 and acceptance and commitment therapy.26 A scene when a pregnant woman would not like to go out because she has gained weight and is not motivated is used as a case.

Self-compassion (module 4)
Self-compassion indicates a positive and caring attitude of a person towards herself in the face of stressful events.27 As a result of this attitude, highly self-compassionate individuals are expected to experience higher individual...
well-being. Three inter-related determine the self-compassionate reactions to negative events and experiences: self-kindness, sense of common humanity and mindfulness. In this module, participants learn the concept of self-compassion and how to express compassion towards themselves. A scene when a pregnant woman suffers from morning sickness and is blaming herself for not being able to work as usual is used as a case.

**Mindfulness (module 5)**

Mindfulness is defined as ‘paying attention in a particular way: on purpose, in the present moment, and non-judgmentally’. Mindful persons are likely to be aware of the physical sensation, thoughts and emotions at that moment, which enables them to stop their usual reactions to a stressful event so that symptoms and problematic behaviours are likely to disappear. In this module, participants learn about the concept of mindfulness and how to practice it through listening to voice guidance. A scene when a pregnant woman feels anxiety due to tension and pain in the lower abdomen in spite of obstetrically normal is used as a case.

**Problem solving (module 6)**

Problem-solving technique is a CB intervention that focuses on training adaptive problem-solving attitudes and skills. A rational problem-solving style contains the systematic application of four problem-solving skills: (1) problem definition and formulation, (2) generation of alternative solutions, (3) decision-making and (4) solution implementation and verification. In this module, participants learn about problem-solving skills to sort out the problem and make a list of solutions, and assertiveness to communicate with their partners confidently. A scene when a pregnant woman wants her partner to do more in housework and childcare is used as a case.

**Outcomes**

Table 2 shows an overview of the outcome measures. Those who have not responded by more than a week after the online questionnaire is distributed will receive a popup message to complete each assessment.

**Primary outcome**

The primary outcome is the onset of MDE during the 32 weeks gestation and 3 months post partum. The onset of

| Table 2 Overview of measurements |
|----------------------------------|
| **Measurement**                  | **Aim**                                      | Baseline (T1) | 32 weeks gestation (T2) | 34 weeks gestation (T3) | 1-week post partum (T4) | 3 months post partum (T5) |
| Primary outcomes                 |                                               |               |                         |                         |                         |                         |
| CIDI                             | Diagnosis of major depressive episode         | ✓             | ✓                        | ✓                        | ✓                        |
| Secondary outcomes               |                                               |               |                         |                         |                         |                         |
| EPDS                             | Depressive symptoms                           | ✓             | ✓                        | ✓                        | ✓                        | ✓                        |
| K₆                               | Psychological distress                        | ✓             | ✓                        | ✓                        | ✓                        | ✓                        |
| EQ-5D-5L                         | Quality of life                               | ✓             | ✓                        | ✓                        | ✓                        | ✓                        |
| SSS-8                            | Somatic symptoms                              | ✓             | ✓                        | ✓                        |                         |                         |
| TRS                              | Resilience                                    | ✓             | ✓                        | ✓                        | ✓                        | ✓                        |
| ISI                              | Insomnia                                      | ✓             | ✓                        | ✓                        | ✓                        | ✓                        |
| CH-RLSq13                        | Restless legs syndrome                        | ✓             | ✓                        | ✓                        | ✓                        | ✓                        |
| Maternal Anxiety Scale for 4–5 months children | Maternal anxiety                     |               |                         |                         |                         | ✓                        |
| Medical costs                    | Medical service use                           | ✓             | ✓                        | ✓                        | ✓                        | ✓                        |
| Implementation and satisfaction  | Implementation outcomes                      |               |                         |                         | ✓                        |                         |
| Adverse effects                  | Physical and mental symptoms                  |               |                         |                         | ✓                        |                         |
| Baseline assessments             |                                               |               |                         |                         |                         |                         |
| Demographics                     |                                               | ✓             |                         |                         |                         |                         |
| VAWS                             |                                               |               |                         |                         |                         | ✓                        |

CH-RLSq13, Cambridge–Hopkins Questionnaire Short Form; CIDI, WHO Composite International Diagnostic Interview 3.0; ED-5D-5L, EuroQol-5 dimension-5 level; EPDS, Edinburgh Postnatal Depression Scale; ISi, Insomnia Severity Index; K₆, Kessler’s Psychological Distress Scale; SSS-8, Somatic Symptom Scale-8; TRS, Tachikawa Resilience Scale; VAWS, Violence Against Women Screen.
MDE during the follow-up will be assessed using the web-based self-administered version of the Japanese WHO-CIDI 3.0 depression section, according to Diagnostic and Statistical Manual of Mental Disorders Fourth Edition (Text Revision).

The web version has been shown to have a good concordance with the clinical diagnosis of MDE and to be reliable in a 1-year test–retest survey. An incident case with MDE will be identified if a respondent reports an episode of MDE at either 32 weeks gestation or 3 months post partum. An onset month for an episode of MDE also will be requested. In addition, two other definitions are applied to identify subthreshold depressive episodes: one requires a shorter duration of symptoms (ie, 7 days or more, rather than 2 weeks or more); the other one requires having a fewer symptoms (ie, having three symptoms or more, instead of five symptoms or more).

Secondary outcomes

**Edinburgh Postnatal Depression Scale (EPDS)**

Depressive symptoms will be measured by the Japanese version of EPDS. EPDS is used most often for screening perinatal depression because it focuses on cognitive symptoms of depression and excludes somatic items that can generate false positives during pregnancy and post partum. It consists of 10 items, with 0–3 points scored per item for a potential scale score of 0–30. The higher scores indicate more severe depressive symptoms. EPDS will be conducted at baseline, 32 weeks gestation, 1-week post partum and 3 months post partum.

**Kessler’s Psychological Distress Scale**

Psychological distress is measured by the Japanese version of K6. K6 consists of six items assessing the frequency with which respondents have experienced symptoms of psychological distress during the past 30 days. The response options range from 0 (none of the time) to 4 (all of the time), and the total score ranges from 0 to 24. The higher scores indicate more severe psychological distress. K6 will be conducted at baseline, 32 weeks gestation, 1-week post partum and 3 months post partum.

**EuroQol-5 dimension-5 level (EQ-5D-5L)**

General health status will be measured by the Japanese version of EQ-5D-5L. It is a five-dimensional utility instrument consisting of domains about morbidity, self-care, usual activities, pain or discomfort, and anxiety or depression. Each domain is divided into five levels of severity (none, slight, moderate, severe, extreme problems or unable to). All responses are converted into a single index score of general health status. EQ-5D-5L will be conducted at baseline, 32 weeks gestation and 3 months post partum.

**Somatic Symptom Scale-8 (SSS-8)**

Somatic symptoms will be measured by Japanese version of SSS-8. SSS-8 consists of eight items that assess the following symptoms: stomach or bowel problems; back pain; pain in the arms, legs, or joints; headaches; chest pain or shortness of breath; dizziness; feeling tired or having low energy; and trouble sleeping. These items comprise the four symptom domains of gastrointestinal, pain, cardiopulmonary and fatigue. Respondents rate how much each symptom has bothered them during the previous 7 days and score each item from 0 to 4: not at all (0), a little bit (1), somewhat (2), quite a bit (3) and very much (4). The total score ranges from 0 to 32. A higher score reflects a more severe somatic symptom burden. SSS-8 will be conducted at baseline, 32 weeks gestation and 3 months post partum.

**Tachikawa Resilience Scale (TRS)**

Resilience will be measured by TRS. TRS consists of 10 items. All items are scored on a 7-point scale from 1 (strongly disagree) to 7 (strongly agree), with a total score ranging from 10 to 70. Higher scores reflect higher resilience. TRS will be conducted at baseline, 32 weeks gestation and 3 months post partum.

**Insomnia Severity Index (ISI)**

Insomnia will be measured by the Japanese version of ISI. ISI consists of seven items assessing the severity of sleep-onset and sleep maintenance difficulties (both nocturnal and early morning awakenings), satisfaction with the current sleep pattern, interference with daily functioning, awareness of impairment attributed to the sleep problem and degree of distress or concern caused by the sleep problem. Each item is rated on a 0–4 scale and the total score ranges from 0 to 28. A higher score suggests more severe insomnia. ISI will be conducted at baseline, 32 weeks gestation and 3 months post partum.

**Cambridge-Hopkins Questionnaire Short Form (CH-RLSq13)**

Restless legs syndrome (RLS) will be measured by the Japanese version of CH-RLSsq13. Diagnosis of RLS is performed using 10 items consisting of questions about discomfort and stiffness of the lower limbs. In addition, two items ask about the degree of pain and the frequency of occurrence and one item asks about the age of onset (relevant to pregnancy in women). CH-RLSsq13 will be conducted at baseline, 32 weeks gestation and 3 months post partum.

**Maternal Anxiety Scale for 4–5-month-old children**

Maternal anxiety will be measured by the Maternal Anxiety Scale for 4–5-month-old children. This scale consists of 34 items. Eleven items assess childcare anxiety, six items assess husbands’ or partners’ support, five items assess childcare satisfaction, four items assess ease of raising children, five items assess a lack of confidence and three items assess presence or absence of advisors. All items are scored on a 4-point scale from 1 (strongly disagree) to 4 (strongly agree). A higher score of each subscale reflects a higher presence of each factor. This scale will be conducted at 3 months post partum.
Medical economic costs
For cost-effectiveness analysis, the presence or absence, frequency and duration of medical service use, and the use of drugs over the prior 3 months will be asked at 32 weeks gestation and 3 months post partum.

Process evaluation
Implementation outcomes
Time spent logged in to each module will be measured. Also, we will evaluate implementation outcomes by self-report via survey. Proctor et al suggested eight conceptually distinct implementation outcomes: acceptability, adoption, appropriateness, feasibility, fidelity, implementation cost, penetration and sustainability.46 However, a systematic review examined implementation outcomes for mental health and behavioural health using evidence-based rating criteria and concluded that the majority of instrumental outcomes were underdeveloped.47 Recently, Weiner et al developed measures of acceptability, appropriateness and feasibility because their outcomes are often used as leading indicators and are conceptually distinct.48 Three of the authors (DN, EO and NS) reviewed the previous literature and selected the possible outcomes for each dimension of acceptability, appropriateness and feasibility. These implementation outcomes and satisfaction with the intervention programme will be asked about at 34 weeks gestation.

Adverse effects
Three of the authors (DN, EO and NS) reviewed the previous literature based on a systematic review, and selected the possible adverse effects of the programme, such as physical symptoms (eg, tired eyes, stiff shoulders), mental symptom (eg, insomnia), dangerous experiences (eg, collide with people while walking and looking at the smartphone), too much use of the smartphone and excessive pressure to learn this programme regularly. These potential adverse effects will be asked about at 34 weeks gestation.

Data collection
All data will be collected by the internet. If the entered data are incomplete, participants will not be able to proceed the assessment.

Sample size calculation
Required sample size was calculated for the primary outcome. New onset of MDE during the observation period in Japan and the effect size in HR are estimated to be 5% and 0.65,49 based on previous studies. Thirty per cent of participants are expected to drop out of the follow-up assessment. Given an α level of 0.05 (two-tailed) and a β level of 0.20, power Cox was performed with STATA V.14.0 and the appropriate sample size was calculated to be 4812. Since a large number of participants using the app will be recruited on 1 day, it is considered difficult to stop recruiting immediately when the sample size is reached. Thus, the sample size was set at 5000.

Randomisation
Participants who meet the inclusion criteria will be randomly allocated to the intervention group or control group. Participants will be stratified into two strata according to the score of K6 (four or less, or five or more) on the baseline survey. MTI will send baseline data to researchers. In addition to the analysis of the whole sample (to examine the universal intervention effect), we will also analyse data by prespecified subgroups (to examine the selective intervention effect). Using a computer-generated random allocation sequence, an independent biostatistician created a stratified permuted-block random table. The block size of this RCT will be fixed at 4. The stratified permuted-block random table will be password protected and blinded to the researcher. Only the research assistant will be able to access it during the work of random allocation. MTI will make the study participants allocated to the intervention group available to view the iCBT programme on the app, based on the allocation provided by the research assistant.

Statistical methods
Main analysis
As described in detail previously,50 a survival analysis will be conducted to test for the effectiveness of the intervention on the time to the onset of MDE while controlling for censoring effects due to the differential length of follow-up or the completion of follow-up without an onset of MDE. Length of follow-up for each participant will be represented by either the number of months between the baseline and the onset of MDE or the end of the follow-up period (3 months post partum, or 32 weeks gestation if a participant dropped out at the 3-month postpartum follow-up), whichever comes first. The cumulative incidence of MDE at 32 weeks gestation and 3-month postpartum follow-up, as well as event-free survivals at every follow-up month, will be estimated using the Kaplan-Meier method; the statistical significance will be tested of the difference between the cumulative proportions of having MDE at 32 weeks gestation and 3-month postpartum follow-ups in the intervention and control groups. A log-rank test will be conducted to test the difference in survival probabilities between the intervention and the control groups. A single covariate Cox discrete time hazard model will also be used to test the difference and estimate the HR, with 95% CIs, for having MDE in the intervention group compared with the control group. The intervention effect will also be estimated, adjusting for dependent censoring and using the inverse probability of the censoring weighted method for conducting a sensitivity analysis.52 The number needed to treat to achieve prevention of one case of the onset of MDE will be calculated at 32 weeks gestation and 3-month postpartum follow-ups. A similar Cox discrete time hazard model also will be conducted using the two types of subthreshold diagnoses of depressive episodes to investigate the effects of iCBT on preventing depressive episodes, including...
subclinical cases. An intention-to-treat (ITT) analysis will be conducted. Multiple imputation will be performed.

Secondary analyses
For secondary outcomes (ie, EPDS, K6, SSS-8, TRS), mixed models for repeated measures analyses will be conducted using a group (intervention or control) × time (baseline, 32 weeks gestation, 1-week postpartum or 3-month postpartum follow-up) interaction as an indicator of the intervention effect. This allows for missing data to be taken into account within the statistical model. The level of statistical significance for all analyses in this study will be set at 0.05 (two-tailed), and 95% CIs will be calculated. The effect size will be estimated in two ways. First, we will estimate a regression coefficient for a group (the intervention group vs the control group) × time (baseline and follow-ups) interaction using the mixed procedure, which will be converted to an effect size by dividing by a pooled SD at baseline and at follow-ups. Second, we will calculate Cohen’s d among completers at baseline for each follow-up. ITT will be conducted as well. All statistical analyses will be conducted using SPSS Statistics V.21.0 (IBM Corp.).

Subgroup analysis
The effectiveness of the programmes may differ according to the initial severity of psychological distress. Therefore, we will analyse the results according to the prespecified subgroups (ie, participants who scored 4 or less/5 or more in K6 at the baseline survey).

Cost-effectiveness analysis
Quality-adjusted life-years will be calculated as the effectiveness, using the EQ-5D-5L, as the area under the curve defined by the unitility values at baseline and follow-ups. As for the costs, the cost of medical service use will be calculated based on the Survey of Medical Care Activities in Public Health Insurance, which shows the treatment expenses covered by public health insurance in each diagnostic category. No intervention costs such as salary for therapists will be calculated because the programme is fully automated. Mean differences for the calculated effectiveness and costs will be compared between the intervention and control group.

Data monitoring and auditing
Because the iCBT programme is not regarded as an invasive intervention, it is not necessary to set up a data monitoring board or to complete auditing in this trial.

Patient and public involvement
We used the function of the app Luna Luna Baby that allows users (pregnant women) to talk to each other about their problems. We extracted essential topics that pregnant women are concerned about based on 6393 text data, and developed programmes for those topics. Even MTI cannot identify the person who posted a text, the text data are anonymised data that cannot be linked. The procedure was approved by the ethic committee of the University of Tokyo. The topics were extracted by using a machine learning approach, based on the latent Dirichlet allocation (LDA). In this approach, morphological analysis was conducted for the text data from the pregnant women, and nouns and adjectives about what they suffer were collected. The LDA model was implemented by Scikit-learn V.0.21.3 in Python. As a result, five topics were extracted: relationship with partners, concern about weight gain, concern about pregnancy check-up, physical symptoms such as pain and dysfunction due to morning sickness. Since pregnancy check-up is considered to be a matter of obstetrics, each module of the iCBT programme has been developed to deal with the remaining four topics. We will not access this chat room during the RCT.

In addition, three women who had experiences of pregnancy and childbirth (two researchers and a research partner with lived experience) were invited to make comments on the intervention programmes based on their experiences and preferences. All of them experienced maternity blues or perinatal depression, though they did not visit psychiatrists. Two researchers above (EO and NS) also were involved in designing this protocol.

Ethics and dissemination
Ethical and safety considerations
Informed consent for the app will be obtained from all participants included in this study after full explanation of the study. Candidates will be informed that their participation is voluntary, and that even after voluntarily participating, they can withdraw from the study at any time and their withdrawal will cause no disadvantage to them. We expect no adverse health effects from this intervention, except possible deterioration in depressive symptoms. We will send messages to those who meet the criteria for MDE in the past month or for lifetime bipolar disorders at baseline to encourage them to see a psychiatrist. The principal investigators will communicate important protocol modification with the institutional review board.

Data confidentiality
The collected data will be stored as linkable anonymising data. The principal investigator will have access to the final dataset after the trial and take responsibility for the integrity of the data and the accuracy of analysis.

Dissemination of research findings
The findings of this study will be disseminated through publications in peer-reviewed international journals. Presentations of the findings will also be offered at relevant research conferences, and local academic symposia and seminars. If important findings are obtained from this study, we will make a press release and provide a plain language summary for users of Luna Luna Baby. The principal investigator will be listed as corresponding authors, and the authorship eligibility will be conform to the International Committee of Medical Journal Editors. If the intervention programmes are found to be
significantly positively effective, the programmes can be made available for all users of the app in the future.

**DISCUSSION**

The greatest strength of this study is to prove the effectiveness of the fully automated smartphone-based CBT programme on preventing both antenatal and postpartum depression. The relatively short, newly developed programmes for pregnant women would be practical and low dropout is expected. Furthermore, this study will assess diagnosis of MDE using CIDI. Many previous studies using iCBT have suggested its preventive effect on depression; however, no previous studies assessed the diagnosis of perinatal depression using the structural interview. This RCT with large sample size can lead to a definitive result.

This study also will evaluate implementation outcomes of the programme. Previous studies using iCBT have assessed the satisfaction with their programme; however, few studies evaluated implementation outcomes including acceptability, adoption, appropriateness, feasibility, fidelity, implementation cost, penetration and sustainability. This study will contribute to the dissemination and implementation of iCBT in the future.

Another strength of this study is to add evidence of maternity blues. Maternity blues is highly prevalent, and it can present a range of symptoms such as intense short-lasting dysphoric mood, irritability, anxiety, sleep disturbance and poor concentration within the first week following childbirth. Maternity blues could lead to postpartum depression, but to our knowledge, no previous studies have shown a preventive strategy to deal with maternity blues. This RCT will clarify whether iCBT during pregnancy can prevent maternity blues.

This study has several limitations. First, all outcomes will be measured by self-report, which could be affected by the perceptions of the participants. Second, users of the app are not regarded as representative of all pregnant women, though approximately one in four pregnant women in Japan is thought to use the app. Therefore, the findings of this study cannot necessarily be generalisable. Third, follow-up period is not long enough, because a sizeable proportion of postpartum depression have onset after 3 months post partum.

**Contributors**

DN conceived and designed the study, DN, Ki, EO, NS and YS contributed creating programmes. NY and NK contributed to the development of study design. KW calculated sample size. KW and YM developed analysis plan. DN wrote the first draft of the manuscript, and all other authors revised the manuscript critically. All authors approved the final version of the manuscript.

**Funding**

This work was supported by Japan Society for the Promotion of Science under a Grant-in-Aid for Scientific Research (A) (19H01073 to DN).

**Disclaimer**

The funder had no role in study design, data collection and analysis, decision to publish or preparation of the manuscript.

**Competing interests**

MTI has been involved in this study as mentioned in the manuscript. NK reports grants from Infocom Corp., Fujitsu, Fujitsu Software Technologies and TAK; personal fees from Occupational Health Foundation, Japan Dental Association, Sekisui Chemicals, Junpukai Health Care Center, Osaka Chamber of Commerce and Industry, outside the submitted work.

**Patient and public involvement**

Patients and/or the public were involved in the design, or conduct, or reporting, or dissemination plans of this research. Refer to the Methods section for further details.

**Patient consent for publication**

Obtained.

**Provenance and peer review**

Not commissioned; externally peer reviewed.

**Open access**

This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/.

**ORCID iDs**

Daisuke Nishi http://orcid.org/0000-0001-9349-3294
Naonori Yasuma http://orcid.org/0000-0002-1216-7639
Norito Kawakami http://orcid.org/0000-0003-1080-2720

**REFERENCES**

1. Wisner KL, Miller ES, Tandon D. Attention to prevention-can we stop perinatal depression before it starts? JAMA Psychiatry 2019;76:355–6.
2. Bennett HA, Einarson A, Taddio A, et al. Prevalence of depression during pregnancy: systematic review. Obstet Gynecol 2004;102:898–909.
3. Hahn-Holbrook J, Cornwell-Hinrichs T, Anaya I. Economic and health predictors of national postpartum depression prevalence: a systematic review, meta-analysis, and meta-regression of 291 studies from 56 countries. Front Psychiatry 2017;8:248.
4. Takehara K, Suto M, Kakue N, et al. Prenatal and early postnatal depression and child maltreatment among Japanese fathers. Child Abuse Negl 2017;70:231–9.
5. Davis EP, Glynn LM, Schetter CD, et al. Prenatal exposure to maternal depression and cortisol influences infant temperament. J Am Acad Child Adolesc Psychiatry 2007;46:737–46.
6. Leech SL, Larkby CA, Day R, et al. Predictors and correlates of high levels of depression and anxiety symptoms among children at age 10. J Am Acad Child Adolesc Psychiatry 2006;45:223–30.
7. Field T, Diego M, Hernandez-Reif M. Prenatal depression effects on the fetus and newborn: a review. Infant Behav Dev 2006;29:445–55.
8. Diego MA, Field T, Hernandez-Reif M, et al. Prenatal depression restricts fetal growth. Early Hum Dev 2009;85:65–70.
9. Stein A, Pearson RM, Goodman SH, et al. Effects of perinatal mental disorders on the fetus and child. Lancet 2014;384:1800–19.
10. Underwood L, Waldie KE, Peterson E, et al. Paternal depression symptoms during pregnancy and after childbirth among participants in the growing up in New Zealand study. JAMA Psychiatry 2017;74:360–9.
11. Lancaster CA, Gold KJ, Flynn HA, et al. Risk factors for depressive symptoms during pregnancy: a systematic review. Am J Obstet Gynecol 2010;202:5–14.
12. US Preventive Services Task Force, Curry SJ, Krist AH, et al. Interventions to prevent perinatal depression: US preventive services Task force recommendation statement. JAMA 2019;321:580–7.
13. Sockol LE. A systematic review of the efficacy of cognitive behavioral therapy for treating and preventing perinatal depression. J Affect Disord 2015;177:7–21.
14. Sockol LE. A systematic review and meta-analysis of interpersonally therapy for perinatal women. J Affect Disord 2018;232:316–28.
15. Sockol LE, Epperson CN, Barber JP. Preventing postpartum depression: a meta-analytic review. Clin Psychol Rev 2013;33:1205–17.
16. Fairburn CG, Patel V. The impact of digital technology on psychological treatments and their dissemination. Behav Res Ther 2017:38:19–25.
17. Loughnan SA, Joubert AE, Grierson A, et al. Internet-Delivered psychological interventions for clinical anxiety and depression in perinatal women: a systematic review and meta-analysis. Arch Womens Ment Health 2019;22:737–50.
18. Barrera AZ, Wickham RE, Murroff RJ. Online prevention of postpartum depression for Spanish- and English-speaking pregnant women: a pilot randomized controlled trial. Internet Interv 2015;2:257–65.
Haga SM, Drozd F, Lisý C, et al. Mamma Mia - A randomized controlled trial of an internet-based intervention for perinatal depression. *Psychol Med* 2019;49:1850–8.

Imamura K, Kawkamaki N, Furukawa TA, et al. Does Internet-based cognitive behavioral therapy (CBT) prevent major depressive episode for workers? A 12-month follow-up of a randomized controlled trial. *Psychol Med* 2015;45:1907–17.

Henshaw C, Foreman D, Cox J. Postnatal blues: a risk factor for postnatal depression. *J Psychosom Obstet Gynaecol* 2004;25:267–72.

Chan A-W, Tetzlaff JM, Gotzsche PC, et al. Spirit 2013 explanation and elaboration: guidance for protocols of clinical trials. *BMJ* 2013;346:e7588.

Kessler RC, Ustün TB. The world mental health (WMH) survey initiative version of the World Health Organization (WHO) composite international diagnostic interview (CIDI). *Int J Methods Psychiatr Res* 2004;13:93–121.

Padesky CA, Greenberger D. *Clinician’s guide to mind over mood*. New York: Guilford Press, 1995.

Cassar J, Ross J, Dahane J, et al. Therapist tips for the brief behavioural activation therapy for depression - revised (BATD-R) treatment manual. Practical wisdom and clinical nuance. *Cin Psychol* 2016;20:46–53.

Hynes SJ, Strohli K, Wilson KG. Acceptance and commitment therapy: an experiential approach to behavior change. New York: Guilford Press, 1999.

Gilbert P. *The compassionate mind: a new approach to life's challenges*. Constable & Robinson: Oakland, 2009.

Sue BS, U. D., O'Donoghue M, et al. The relationship between self-compassion and well-being: a meta-analysis. *Appl Psychol Health Well Being* 2015;7:340–64.

Kabat-Zinn J, Go WY. *There you are: mindfulness meditation in everyday life*. New York: Hyperion Books, 1994.

D'Ozurnil TJ, Dittfried MR. Problem solving and behavior modification. *J Abnorm Psychol* 1971;78:107–26.

Cox JL, Holden JM, Sagovsky R. Detection of postnatal depression: development of the 10-item Edinburgh postnatal depression scale. *Br J Psychiatry* 1987;150:782–6.

Okano T, Matsu S, Masui F, et al. Validation and reliability of Japanese version of the EPDS. *Arch Psychiatr Diag Clin Evaluat* 1996;7:525–33.

Kessler RC, Andrews G, Colpe LJ, et al. Short scoring scales to monitor population psychopathology and trends in non-specific psychological distress. *Psychol Med* 2002;32:959–76.

Furukawa TA, Kawkamaki N, Saitoh M, et al. The performance of the Japanese version of the K6 and K10 in the world mental health survey Japan. *Int J Methods Psychiatr Res* 2008;17:152–8.

Haydn M, Gudex C, Lloyd A, et al. Development and preliminary testing of the new five-level version of EQ-SD (EQ-5D-5L). *Qual Life Res* 2011;20:1727–36.

van Hout B, Janssen MF, Feng Y-S, et al. Interim scoring for the EQ-5D-5L: mapping the EQ-5D-5L to EQ-5D-3L value sets. *Value Health* 2012;15:708–15.

Ikeda S, Ishiuchi T, Ishikawa H, et al. Developing a Japanese version of the EQ-5D-5L value set. *J Natl Inst Public Health* 2015;64:47–55.

Gierk B, Kohlmann S, Kroenke K, et al. The somatic symptom scale-8 (SSS-8): a brief measure of somatic symptom burden. *JAMA Intern Med* 2014;174:409–17.

Matsuda K, Oka H, Kawaguchi M, et al. Development of a Japanese version of the somatic symptom Scale-8: psychometric validity and internal consistancy. *Gen Hosp Psychiatry* 2017;45:7–11.

Nishi D, Uehara R, Yoshikawa E, et al. Culturally sensitive and universal measure of resilience for Japanese populations: Tachikawa resilience scale in comparison with resilience scale 14-item version. *Psychiatry Clin Neurosci* 2013;67:174–81.

Bastien CH, Vallières A, Morin CM. Validation of the insomnia severity index as an outcome measure for insomnia research. *Sleep Med* 2001;2:297–307.

Munezawa T, Morin CM, Inoue Y. Development of the Japanese version of the insomnia severity index (ISI-J) Seishinkachirogyoku., 2009: 24, 219–25.

Allen RP, Burchell BJ, MacDonald B, et al. Validation of the self-completed Cambridge-Hopkins questionnaire (CH-RLSq) for ascertainment of restless legs syndrome (RLS) in a population survey. *Sleep Med* 2009;10:1097–100.

Kondo H, Okada M, Eto H. Development of Cambridge-Hopkins questionnaire 13 Japanese version short form (CH-RLSq13) version 2.1 in the assessment of restless legs syndrome (in Japanese), 2016: 577–84.

Yoshida H, Yamanaka T, Kono G. The study for the development of maternal anxiety scales-1: models for mothers rearing 4 - 5 month-old and 10 - 11 month-old infants, 2013: 680–9.

Proctor E, Silmeme H, Raghavan R, et al. Outcomes for implementation research: conceptual distinctions, measurement challenges, and research agenda. *Adm Policy Ment Health* 2011;38:65–76.

Lewis CC, Fischer S, Weiner BJ, et al. Outcomes for implementation science: an enhanced systematic review of instruments using evidence-based rating criteria. *Implement Sci* 2015;10:155.

Weiner BJ, Lewis CC, Stanick C, et al. Psychometric assessment of three instruments of caregiver postnatal depression severity measure. *Implement Sci* 2017;12:108.

Cuipers P, van Straten A, Smit F, et al. Preventing the onset of depressive disorders: a meta-analytic review of psychological interventions. *Am J Psychiatry* 2008;165:1272–80.

Imamura K, Kawkamaki N, Furukawa TA, et al. Effects of an Internet-based cognitive behavioural therapy intervention on depressive episodes among workers: a protocol for a randomised controlled trial. *BMJ Open* 2015;5:e007590.

Ministry of Health W. Health insurance in 2016 (in Japanese), 2016. Available: https://www.mhlw.go.jp/ginkou/sisinyo/tyosa16/